Donanemab for lowering amyloid in down syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 35 and 50 years old.
- You must have Down syndrome (including any form of trisomy 21).
- You must not have been diagnosed with dementia.
- You need to have high levels of a protein called amyloid in your brain (shown by a special scan).
- You must have a family member or friend (a 'study partner') who can spend at least 5 hours per week with you and accompany you to study visits.
- You must be able to have MRI and PET scans (no metal implants, pacemaker, or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a monthly infusion drug called donanemab, which aims to clear amyloid plaques (a hallmark of Alzheimer's) from the brain, potentially slowing memory decline in people with early Alzheimer's disease. Participants will receive the drug as part of this study.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This trial is testing whether a form of vitamin B3 (called NAD) can help prevent or slow down Alzheimer's disease in people with Down syndrome. The goal is to see if this supplement can protect brain cells and improve memory or thinking.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.